PRTA vs. DVAX, URGN, AKBA, PBYI, MRNS, NUVL, ALKS, PRGO, CRNX, and AXSM
Should you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Dynavax Technologies (DVAX), UroGen Pharma (URGN), Akebia Therapeutics (AKBA), Puma Biotechnology (PBYI), Marinus Pharmaceuticals (MRNS), Nuvalent (NUVL), Alkermes (ALKS), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical preparations" industry.
Dynavax Technologies (NASDAQ:DVAX) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation.
Prothena received 133 more outperform votes than Dynavax Technologies when rated by MarketBeat users. Likewise, 70.67% of users gave Prothena an outperform vote while only 65.77% of users gave Dynavax Technologies an outperform vote.
97.0% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 3.0% of Dynavax Technologies shares are owned by insiders. Comparatively, 28.2% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Dynavax Technologies has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.
Dynavax Technologies has a net margin of 3.91% compared to Dynavax Technologies' net margin of -193.17%. Prothena's return on equity of 1.52% beat Dynavax Technologies' return on equity.
Dynavax Technologies has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.
In the previous week, Prothena had 4 more articles in the media than Dynavax Technologies. MarketBeat recorded 11 mentions for Prothena and 7 mentions for Dynavax Technologies. Dynavax Technologies' average media sentiment score of 0.68 beat Prothena's score of 0.26 indicating that Prothena is being referred to more favorably in the news media.
Dynavax Technologies presently has a consensus price target of $25.33, suggesting a potential upside of 111.29%. Prothena has a consensus price target of $67.00, suggesting a potential upside of 221.96%. Given Dynavax Technologies' higher possible upside, analysts clearly believe Prothena is more favorable than Dynavax Technologies.
Summary
Dynavax Technologies and Prothena tied by winning 9 of the 18 factors compared between the two stocks.
Get Prothena News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prothena Competitors List
Related Companies and Tools
